{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:36:29Z","timestamp":1791995789651,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.intimp.2020.106481","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T19:02:47Z","timestamp":1587754967000},"page":"106481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis"],"prefix":"10.1016","volume":"83","author":[{"given":"Feng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2020.106481_b0005","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10408440903044928","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005","volume":"39","author":"Price","year":"2009","journal-title":"Crit. Rev. Toxicol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106481_b0010","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106481_b0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1445-5994.2012.02925.x","article-title":"Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia","volume":"43","author":"Kao","year":"2013","journal-title":"Int. Med. J."},{"key":"10.1016\/j.intimp.2020.106481_b0020","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.21037\/jtd.2017.12.88","article-title":"New horizons from immunotherapy in malignant pleural mesothelioma","volume":"10","author":"Calabro","year":"2018","journal-title":"J. f Thoracic Dis."},{"issue":"3","key":"10.1016\/j.intimp.2020.106481_b0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respiratory Med."},{"issue":"8","key":"10.1016\/j.intimp.2020.106481_b0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant Mesothelioma Mortality - United States, 1999\u20132015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"2","key":"10.1016\/j.intimp.2020.106481_b0035","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: Potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.intimp.2020.106481_b0040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.106481_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1074-3","article-title":"The role of exosomal PD-L1 in tumor progression and immunotherapy","volume":"18","author":"Xie","year":"2019","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2020.106481_b0050","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12094-018-1970-9","article-title":"The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis","volume":"21","author":"Ni","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.intimp.2020.106481_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5466-y","article-title":"The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis","volume":"19","author":"Qiu","year":"2019","journal-title":"Bmc Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2020.106481_b0060","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.intimp.2020.106481_b0065","first-page":"1036","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis, Journal of thoracic oncology : official publication of the International Association for the Study of","volume":"9","author":"Mansfield","year":"2014","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2020.106481_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.106481_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106481_b0080","first-page":"850","article-title":"The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma, Journal of thoracic oncology : official publication of the International Association for the Study of","volume":"12","author":"Thapa","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2020.106481_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","article-title":"Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma","volume":"71","author":"Inaguma","year":"2018","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106481_b0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106481_b0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thoracic Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.intimp.2020.106481_b0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2019.02.005","article-title":"High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes","volume":"130","author":"Ahmadzada","year":"2019","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"5","key":"10.1016\/j.intimp.2020.106481_b0105","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.intimp.2020.106481_b0110","doi-asserted-by":"crossref","unstructured":"S. Muller, W. Victoria Lai, P.S. Adusumilli, P. Desmeules, D. Frosina, A. Jungbluth, A. Ni, T. Eguchi, W.D. Travis, M. Ladanyi, M.G. Zauderer, J.L. Sauter, V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma, Modern Pathol.: Off. J. United States Can. Acad. Pathol., Inc (2019).","DOI":"10.1038\/s41379-019-0364-z"},{"issue":"3","key":"10.1016\/j.intimp.2020.106481_b0115","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","article-title":"Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma","volume":"46","author":"Sobhani","year":"2019","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2020.106481_b0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Int. Med."},{"issue":"24","key":"10.1016\/j.intimp.2020.106481_b0125","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.intimp.2020.106481_b0130","unstructured":"G.A. Wells, B. Shea, D. O'Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (2009)."},{"key":"10.1016\/j.intimp.2020.106481_b0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"issue":"11","key":"10.1016\/j.intimp.2020.106481_b0140","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2020.106481_b0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13665-019-0224-9","article-title":"Malignant Pleural Mesothelioma: an Update for Pulmonologists","volume":"8","author":"Sidhu","year":"2019","journal-title":"Curr. Pulmonol. Reports"},{"issue":"4","key":"10.1016\/j.intimp.2020.106481_b0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/carcin\/bgz004","article-title":"Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database","volume":"40","author":"van Gerwen","year":"2019","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.intimp.2020.106481_b0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","article-title":"Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma","volume":"51","author":"Ritprajak","year":"2015","journal-title":"Oral. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106481_b0160","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2020.106481_b0165","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106481_b0170","article-title":"Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106481_b0175","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106481_b0180","doi-asserted-by":"crossref","first-page":"E147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.intimp.2020.106481_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111798","article-title":"Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.intimp.2020.106481_b0190","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.intimp.2020.106481_b0195","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"New England J. Med."},{"issue":"25","key":"10.1016\/j.intimp.2020.106481_b0200","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New England J. Med."},{"issue":"25","key":"10.1016\/j.intimp.2020.106481_b0205","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011004","article-title":"Clinicopathological and prognostic significance of PD-L1 expression in sarcoma A systematic review and meta-analysis","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2020.106481_b0210","doi-asserted-by":"crossref","DOI":"10.1177\/1724600819876952","article-title":"Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis","author":"Cao","year":"2019","journal-title":"Int. J. Biol. Markers"},{"issue":"1","key":"10.1016\/j.intimp.2020.106481_b0215","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.5301\/jbm.5000225","article-title":"Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis","volume":"32","author":"Pyo","year":"2017","journal-title":"Int. J. Biol. Markers"},{"issue":"4","key":"10.1016\/j.intimp.2020.106481_b0220","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tbj.12753","article-title":"Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis","volume":"23","author":"Wang","year":"2017","journal-title":"Breast J."},{"key":"10.1016\/j.intimp.2020.106481_b0225","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3389\/fonc.2019.01111","article-title":"Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients","volume":"9","author":"Liu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2020.106481_b0230","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-019-00572-9","article-title":"The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis","author":"Wen","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.intimp.2020.106481_b0235","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.21037\/jtd.2017.10.125","article-title":"The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review","volume":"10","author":"Ali","year":"2018","journal-title":"J. Thoracic Dis."},{"issue":"3","key":"10.1016\/j.intimp.2020.106481_b0240","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann. Thoracic Surg."},{"key":"10.1016\/j.intimp.2020.106481_b0245","doi-asserted-by":"crossref","unstructured":"K. Kadota, K. Suzuki, C. Colovos, C.S. Sima, V.W. Rusch, W.D. Travis, P.S. Adusumilli, A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma, Modern Pathol.: Off. J. United States and Can. Acad. Pathol., Inc 25(2) (2012) 260\u2013271.","DOI":"10.1038\/modpathol.2011.146"},{"key":"10.1016\/j.intimp.2020.106481_b0250","doi-asserted-by":"crossref","unstructured":"S. Klebe, N.A. Brownlee, A. Mahar, J.L. Burchette, T.A. Sporn, R.T. Vollmer, V.L. Roggli, Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases, Modern Pathol.: Off. J. United States and Can. Acad. Pathol., Inc 23(3) (2010) 470\u2013479.","DOI":"10.1038\/modpathol.2009.180"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920306639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920306639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:18:03Z","timestamp":1761585483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920306639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":50,"alternative-id":["S1567576920306639"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106481","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106481"}}